Biotech Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
AstraZeneca
Studies examine Seroquel in combination with antidepressant therapy in patients with depression
June 23rd, 2006
AstraZeneca (AZN) announced results of two clinical studies that examined Seroquel (quetiapine fumarate) in combination with antidepressant therapy in patients with depression. One study evaluated the use of Seroquel in combination with antidepressant therapies (SSRI/SNRI medications) to improve residual depressive and anxiety symptoms in patients with major depressive disorder. Another study examined the benefit of Seroquel when added to SSRI/SNRI therapies in patients with treatment-resistant depression. These two studies were presented at the annual meeting of the American Psychiatric Association (APA). Seroquel is approved for the treatment of...
Source: Biotech Law Weekly (2006-06-23)
|
